A comprehensive view of Merck KGaA. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
Merck KGaA partners with C4 Therapeutics in a US$740.0M deal to develop cancer-fighting protein degraders; Merck will finance C4’s discovery work and manage future clinical development
Published:
March 04, 2024
by FierceBiotech
|
Merck integrates p-Chip's microtransponder technology as a crypto-anchor into cyber-physical trust framework that allows customers to create digital twins of single physical products, prove their authenticity throughout product life cycle
Published:
December 12, 2023
by Merck KGaA
|
MilliporeSigma opens two new mRNA drug substance manufacturing sites in Germany; the firm is first contract testing, development, and manufacturing company with integrated services for all stages of mRNA development, manufacturing, and commercialization
Published:
September 29, 2023
by Biopharm International
|
Merck KGaA’s MilliporeSigma expands its global mRNA network with two new drug substance manufacturing sites in Darmstadt and Hamburg, Germany; the facilities to support all stages of mRNA development and commercialization
Published:
September 27, 2023
by FiercePharma
|
Merck wraps up first four years of SMASH Packaging, a global approach based on four pillars--SHRINK, SECURE, SWITCH and SAVE; since SMASH Packaging’s inception, over 100 packaging improvement projects have been completed or are underway
Published:
July 31, 2023
by 3BL Media
|
Ask us about our Tissue & Hygiene market view